Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Jul 17, 2026
Affirm Holdings (AFRM) Climbs +12.9% Over 30 Days on Analyst Upgrades and Fresh Partnerships

Affirm Holdings (AFRM) Climbs +12.9% Over 30 Days on Analyst Upgrades and Fresh Partnerships

Key Takeaways

  • Affirm Holdings (AFRM) climbed approximately 12.9% over the last 30 days, rising from a closing price of $70.73 on June 17, 2026, to $79.84 on July 16, 2026.
  • The stock has gained roughly 23.8% over the broader quarter, driven by a series of analyst upgrades, strong earnings results, and expanding merchant partnerships.
  • Key catalysts include a $1.7 billion forward-flow agreement with CPP Investments, new partnerships with Bed Bath & Beyond and Backcountry, and an upgrade to "strong-buy" from Barclays.
  • Analyst sentiment remains broadly positive, with firms including Citigroup, Susquehanna, and Piper Sandler issuing price targets between $85 and $115.
  • Ongoing debates about leverage, credit quality, and consumer health continue to shape the risk-reward profile for investors.

Affirm Holdings (AFRM) Company Overview and Market Position

Affirm Holdings, Inc. is a San Francisco-based financial technology company that operates a buy-now-pay-later (BNPL) platform enabling consumers to split purchases into fixed, transparent installment loans with no hidden fees. Founded in 2012, the company partners with over 515,000 active merchants across categories including retail, travel, outdoor recreation, and home goods. Affirm generates revenue through merchant fees and interest income on consumer loans, underwriting each transaction individually using proprietary risk-assessment technology. Its product ecosystem includes a consumer-facing app, the Affirm Card, virtual card capabilities, and integrated checkout solutions. The company competes with traditional credit card issuers and fintech peers such as SoFi Technologies (SOFI) and PayPal (PYPL), while differentiating itself through a no-late-fee model and real-time credit decisioning. Investors follow AFRM closely given its rapid merchant network expansion, gross merchandise volume growth, and the ongoing evolution of the BNPL industry from transaction financing toward everyday money management. When I scanned comparable names in the space, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Affirm Holdings (AFRM) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, Affirm shares moved from a closing price of $70.73 on June 17, 2026, to $79.84 at market close on July 16, 2026, representing a gain of approximately 12.9%. The stock experienced notable momentum in late June, rallying from $62.81 on June 10 to an intra-period peak of $86.55 on July 2 before consolidating in the $80–$85 range through mid-July. Over the broader quarter starting from April 17, when shares closed at $64.50, the stock has surged roughly 23.8%, reflecting sustained upward momentum. The quarterly trend was marked by a powerful April rally of over 40%, followed by a choppy May and a renewed advance in late June through early July. The 50-day simple moving average has climbed to approximately $72, signaling strong near-term momentum, while the 200-day moving average sits near $63.50, underscoring longer-term appreciation from the $45 range seen in early April.

What Drove AFRM Stock Price in the Last 30 Days

The 12.9% gain over the last 30 days was fueled by a confluence of positive analyst actions, strategic partnerships, and improving financial metrics. On June 25, Susquehanna raised its price target to $105, citing growth potential based on Adobe Analytics data and management discussions. Piper Sandler followed on June 29, reiterating an Overweight rating and setting a $103 target, arguing that BNPL is entering a second phase centered on everyday money management — a shift that favors Affirm's expanding product suite, including the Affirm Card and Edge offering. On July 1, Citigroup raised its target from $100 to $115, maintaining a Buy rating. On July 10, Barclays upgraded the stock to "strong-buy," reinforcing the bullish sentiment. On the partnership front, Affirm announced a significant $1.7 billion forward-flow agreement with CPP Investments, expandable to $2.2 billion, which is expected to support approximately $8 billion in consumer loan volume over two years. The company also added Bed Bath & Beyond and Backcountry to its merchant network, broadening its reach in home goods and outdoor recreation. The appointment of former Capital One executive Ryan Schneider to the board further signaled a focus on credit and underwriting expertise. On the earnings front, the company's Q3 fiscal 2026 results delivered EPS of $0.30, well above the $0.17 consensus, though revenue of $943.95 million came in below analyst estimates of roughly $995 million. Citizens maintained a Market Outperform rating and $85 target on July 16, noting stable credit data and resilient consumer spending despite energy price concerns.

What Drove AFRM Stock Performance Over the Last Quarter

Affirm's 23.8% quarterly gain was underpinned by a powerful April rebound, during which the stock rallied over 40% as Morgan Stanley named AFRM a "Top Pick," citing upward estimate revision potential and calling private credit fears "overdone." The company's expanded partnership with Stripe to support agentic commerce through Shared Payment Tokens added to the technological narrative. The May 7 Q3 earnings release, which showed a 32.7% year-over-year revenue increase and a swing to GAAP profitability, validated the bullish thesis. The company's Investor Day in mid-May provided updated medium-term guidance, with management indicating revenue growth expectations above 20% and refining margin targets — a presentation Citi had flagged ahead of time with a "90-Day Catalyst Watch" designation. Throughout the quarter, multiple analyst firms raised price targets, including Cantor Fitzgerald (from $61 to $80), Deutsche Bank (to $85), and Truist (to $80). The merchant count grew 44% year-over-year to 515,000, and gross merchandise volume rose 35% to $11.6 billion in Q3 alone, with full-year GMV guidance of $49.265–$49.565 billion. These metrics reinforced the narrative that Affirm's network effect is strengthening across diverse retail verticals.

Exploring Automated Trading Strategies for Names Like AFRM

In my own research process, I sometimes look at automated approaches to complement fundamental analysis, especially when monitoring momentum in fintech names. For traders seeking automated strategies tailored to stocks like Affirm, Tickeron's Trending AI Robots page offers a curated selection of top-performing AI trading bots. Tickeron hosts hundreds of AI-driven bots that trade thousands of tickers across diverse strategies, timeframes, and performance metrics, but only the most relevant and consistently strong performers are highlighted in this section. Each bot uses pattern recognition and algorithmic analysis to identify potential trading opportunities without human emotional bias. Bots vary in approach — some focus on short-term swing trades, while others target longer-duration trends — allowing users to find strategies aligned with their own risk tolerance and investment style. Exploring the Trending AI Robots page can help investors discover automated tools designed to navigate evolving market conditions.

AFRM Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several factors will influence Affirm's trajectory. The company's next quarterly earnings report will be closely scrutinized for sustained profitability, GMV growth, and credit performance metrics amid ongoing debate about consumer health and delinquency rates. Macroeconomic conditions — particularly interest rate policy, energy prices, and employment data — will play a decisive role in shaping consumer borrowing behavior and Affirm's funding costs. The company's ability to maintain and expand its merchant network, especially with large enterprise partners, remains central to its growth narrative. Regulatory developments around BNPL products, including potential consumer protection rules and fee disclosure requirements, could introduce new compliance costs. Investor attention will also focus on the performance of newer initiatives such as the Affirm Card and AdaptAI-driven margin optimization. Competitive pressure from traditional banks and fintech rivals entering the installment-payment space may test Affirm's pricing power and market share. While analyst consensus remains tilted toward Buy with an average price target near $90, the wide dispersion of targets — from $79 to $115 — reflects genuine uncertainty about the pace at which Affirm can convert merchant expansion into sustained, capital-efficient profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AFRM

Momentum Indicator for AFRM turns positive, indicating new upward trend

AFRM saw its Momentum Indicator move above the 0 level on August 03, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned positive. In of the 78 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AFRM's RSI Indicator exited the oversold zone, of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AFRM just turned positive on August 05, 2026. Looking at past instances where AFRM's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

AFRM moved above its 50-day moving average on August 03, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for AFRM crossed bullishly above the 50-day moving average on August 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AFRM advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .

AFRM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 250 cases where AFRM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where AFRM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AFRM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AFRM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AFRM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock worse than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.789) is normal, around the industry mean (4.346). AFRM's P/E Ratio (69.732) is considerably higher than the industry average of (16.768). Projected Growth (PEG Ratio) (0.770) is also within normal values, averaging (1.884). Dividend Yield (0.000) settles around the average of (0.069) among similar stocks. P/S Ratio (6.978) is also within normal values, averaging (6.254).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are VISA (NYSE:V), Mastercard (NYSE:MA), American Express Company (NYSE:AXP), Capital One Financial (NYSE:COF), PayPal Holdings (NASDAQ:PYPL), Synchrony Financial (NYSE:SYF), SLM Corp (NASDAQ:SLM), Bread Financial Holdings (NYSE:BFH), LexinFintech Holdings Ltd (NASDAQ:LX).

Industry description

A savings bank primary function is to take deposits and paying interest on those deposits. Originating in Europe during the 18th century, these banks were generally introduced to incentivize people of all stripes to save money and park them with banks. By the 1990s, the internet ushered in online savings banks that allowed savers to deposit/transact with banks digitally, without requiring to visit a branch office. Savings banks have potentially encouraged lower-income population to save and have access to a financial institution to earn interest on their money. New York Community Bancorp, Inc, Webster Financial Corporation, Washington Federal, Inc. are examples of savings banks.

Market Cap

The average market capitalization across the Savings Banks Industry is 34.24B. The market cap for tickers in the group ranges from 1.72M to 671.74B. V holds the highest valuation in this group at 671.74B. The lowest valued company is DXF at 1.72M.

High and low price notable news

The average weekly price growth across all stocks in the Savings Banks Industry was 0%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 10%. VRM experienced the highest price growth at 36%, while OPFI experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Savings Banks Industry was -17%. For the same stocks of the Industry, the average monthly volume growth was -17% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 64
Price Growth Rating: 54
SMR Rating: 49
Profit Risk Rating: 75
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
AFRM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry SavingsBanks

Profile
Details
Industry
N/A
Address
650 California Street
Phone
+1 415 960-1518
Employees
2206
Web
https://www.affirm.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.